Sanofi hosted on April 23, 2020 a live webcast and conference call on the detailed Phase 2b results of the investigational BTK inhibitor ('168) in relapsing multiple sclerosis.
INVESTOR PRESENTATIONS • April 23, 2020
Sanofi hosted on April 23, 2020 a live webcast and conference call on the detailed Phase 2b results of the investigational BTK inhibitor ('168) in relapsing multiple sclerosis.
If you wish to continue to this external website, click Proceed.
It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.